• JAPANESE
  • ENGLISH
HOME > Corporate Profile

Corporate Profile

Principle

ReproCELL Inc. is a biotechnology company established for the purpose of contributing to people's health and welfare using the stem cell technologies developed by Prof. Nakatsuji in Institute for Frontier Medical Sciences, Kyoto University and Prof. Nakauchi in The Institute of Medical Sciences, The University of Tokyo.
We are focusing on "Stem Cell Technology" including ES/iPS cells and somatic stem cells. Our technologies have applications in the three fields of "Medical practice", "Drug screening and Toxicity testing", and "Research reagents".

Corporate profile

Company name ReproCELL Incorporated
Established Feburaury 26th, 2003
Capital 431 Million Yen
Location
Head Office/
Laboratory		 ShirokanedaiUsui Bldg. 7F
3-16-13,Shirokanedai,
Minato-ku,Tokyo
108-0071,Japan
Number of members 14
Board of Directors
CEO Chikafumi Yokoyama, Ph.D.
CTO Yasuyuki Asai, Ph.D.
Director Hiromitsu Nakauchi, M.D., Ph. D.

Director

Yoshiyuki Yamakawa (HIBIKI Partners Co.Ltd., CEO)

Auditor

Yukari Nakajima
Business Areas
  • Research reagents for ES/iPS cells (Medium, Antibodies, etc)
  • QTempo Drug screening and Toxicity testing using ES/iPS cells (QT prolongation assay by using beating cardiomyocytes)
  • Primary cell development for drug screening and assay services
  • Clinical diagnostics related to transplantation (HLA related tests and Follow-up tests)
  • Flow cytometry service
  • Ex-vivo expansion of hematopoietic stem cells
Related research organizations Institute for Integrated Cell-Material Sciences, Kyoto University
The Institute of Medical Sciences, The University of Tokyo
Graduate School of Medicine, Chiba University
Stem cell and drug discovery institute
Scientific Advisors Prof. Atsushi Iwama
Graduate School of Medicine, Chiba University
Assoc. Prof. Hirofumi Suemori
Institute for Frontier Medical Sciences, Kyoto University
Assoc. Prof. Takashi Tada
Institute for Frontier Medical Sciences, Kyoto University
Assistant Prof. Taeko Naruse
Department of Molecular Pathogenesis, Division of Pathophysiology,
Medical Research Institute, Tokyo Medical and Dental University
CEO Chikafumi Yokoyama, Ph.D
Biography
Dr. Yokoyama joined ReproCELL Inc. in 2004 as a general manager of business development division and became Chief Executive Officer in 2005. He has been responsible for all aspects of new product management, alliance, and fund raising. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is intensively carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, he worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, to serve as a R&D leader of a new project. He received his Ph.D. in chemistry from Tokyo University in 1996.

Top of the page